Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index, and 1 are not checked yet.

Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder Cancer

Open access

Abstract

Background: Urothelial bladder cancer (UBC) is a highly prevalent disease in North America, however its optimal management remains elusive. The contribution of B cell associated responses is poorly understood in bladder cancer. Lymphoid neogenesis is a hallmark of an active immune response at tumor sites that sometimes leads to formation of tertiary lymphoid structures (TLS) that resemble germinal centers formed in secondary lymphoid organs. Objective: This study was conducted with an aim to investigate the presence and characteristics of TLS in UBC with a focus to compare and contrast the TLS formation in treatment naive low grade non-muscle invasive (NMIBC) and muscle invasive bladder cancers (MIBC). Methods: The study cohort consisted of transurethral bladder resection tumour (TURBT) specimens from 28 patients. Sections showing lymphoid aggregates in hematoxylin and eosin (H&E) stained TURBT specimens were further subjected to multi-color immunohistochemistry using immune cell markers specific to CD20 + B cells, CD3 + and CD8 + T cells, PNAd + high endothelial venules, CD208 + mature dendritic cells, CD21 + follicular dendritic cells to confirm the hallmarks of classical germinal centers. Results: Our pilot study investigating the presence of TLS in bladder cancer patients is the first to demonstrate that well-formed TLS are more common in aggressive high grade MIBC tumors compared to low grade NIMBC. Conclusions: These novel findings suggest B cell mediated anti-tumour humoral immune responses in bladder cancer progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/blc-170120

Cites

23 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig.1 Developmental continuum of TLS in bladder tumours. Multi-color IHC performed on 5 μm thick sections from formalin fixed paraffin embedded bladder tumour tissue to reveal features associated with the TLS architecture. Different Types of aggregates and immune cell distributions were defined as previously described by Kroeger et al., [20], A) Type I B) Type 2 C) Type 3 and D) Type 4 aggregates. E) Well formed tertiary lymphoid structure in high grade muscle invasive bladder tumour showing CD3+ (green) and CD8+ T lymphocytes (purple), CD20+ B lymphocytes (pink), CD21+ follicular dendritic cells (blue), CD208+ mature dendritic cells (black), PNAd+ high endothelial venule (brown).
Fig.1 Developmental continuum of TLS in bladder tumours. Multi-color IHC performed on 5 μm thick sections from formalin fixed paraffin embedded bladder tumour tissue to reveal features associated with the TLS architecture. Different Types of aggregates and immune cell distributions were defined as previously described by Kroeger et al., [20], A) Type I B) Type 2 C) Type 3 and D) Type 4 aggregates. E) Well formed tertiary lymphoid structure in high grade muscle invasive bladder tumour showing CD3+ (green) and CD8+ T lymphocytes (purple), CD20+ B lymphocytes (pink), CD21+ follicular dendritic cells (blue), CD208+ mature dendritic cells (black), PNAd+ high endothelial venule (brown).CC BY-NC · PubMed Central
Fig.2 Lymphoid aggregates in low grade MIBC. H & E stained 5 μm thick FFPE section of a low grade NMIBC tumour showing lymphoid aggregation (A, C and E) further confirmed by staining with multi-color IHC (B, D and F) markers specific to TLS including showing CD20+ B cells (pink) and CD8+ T cells (purple).
Fig.2 Lymphoid aggregates in low grade MIBC. H & E stained 5 μm thick FFPE section of a low grade NMIBC tumour showing lymphoid aggregation (A, C and E) further confirmed by staining with multi-color IHC (B, D and F) markers specific to TLS including showing CD20+ B cells (pink) and CD8+ T cells (purple).CC BY-NC · PubMed Central
Fig.3 TLS in high grade MIBC. H & E stained 5 μm thick FFPE section of MIBC tumour showing TLS like lymphoid aggregation (A, C and E) further confirmed by staining with multi-color IHC (B, D and F) markers specific to TLS including, CD3+ (green) and CD8+ T cells (purple), CD20+ B cells (pink), CD21+ follicular dendritic cells (blue), CD208+ mature dendritic cells (black), PNAd+ high endothelial venule (brown).
Fig.3 TLS in high grade MIBC. H & E stained 5 μm thick FFPE section of MIBC tumour showing TLS like lymphoid aggregation (A, C and E) further confirmed by staining with multi-color IHC (B, D and F) markers specific to TLS including, CD3+ (green) and CD8+ T cells (purple), CD20+ B cells (pink), CD21+ follicular dendritic cells (blue), CD208+ mature dendritic cells (black), PNAd+ high endothelial venule (brown).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 16

  1. Babjuk M, 2012, Actas Urol EsServicio de Urologia, Hospital Motol, Segunda Facultad de Medicina, Universidad Carolina, Praga, Republica Checa. Marek.badjuk@ lfmotol.cuni.cz: AEU. Published by Elsevier Espana, 36, 389
  2. Lima L, 2012, Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, 4200-072 Porto, Portugal, 2012, 232609
  3. Schreiber RD, 2011, Science. Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA. schreiber@immunology.wustl.edu, 331, 1565
  4. Galon J, 2014, J Pathol. INSERM, U872, Laboratory of Integrative Cancer Immunology, Paris, France; Universite Paris Descartes, Paris, France; Centre de Recherche des Cordeliers, Universite Pierre et Marie Curie Paris 6, France.: The Authors. Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland, 232, 199
  5. Galon J, 2016, J Transl Med [Internet]. BioMed Central, 1
  6. Kyi C, 2014, Published by Elsevier B.V, 588, 368
  7. 10.1038/nri3804 · DOI · Paper page
  8. Dieu-Nosjean MC, 2014, Trends Immunol. Laboratory “Cancer, Immune Control and Escape”, INSERM U1138 Cordeliers Research Centre, Paris, France; University Pierre and Marie Curie, UMRS 1138, Paris, France; University Paris Descartes, UMRS 1138, Paris, France.; Laboratory ’Cancer, Immune Control: Elsevier Ltd, 35, 571
  9. Coppola D, 2011, Am J Pathol. Anatomic Pathology Division, Moffitt Cancer Center, Tampa, FL 33612-9497, USA.: American Society for Investigative Pathology. Published by Elsevier Inc, 179, 37
  10. Dieu-Nosjean MC, 2008, J Clin Oncol. Laboratoire Microenvironnement, Immunitaire et Tumeurs, Institut National de la Sante et de la Recherche Medicale (INSERM) U872, Centre de Recherche des Cordeliers, Paris cedex 06, France. mc.dieu-nosjean@crc.jussieu.fr, 26, 4410
  11. Martinet L, 2011, Cancer Res. CNRS, IPBS (Institut de Pharmacologie et de Biologie Structurale), INSERM, U563, Centre de Physiopathologie de Toulouse-Purpan, Toulouse, France.: AACR, 71, 5678
  12. Pitzalis C, 2014, Nat Rev. Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.; Cardiff Institute for Infection and I, 14, 447
  13. Finkin S, 2015, Nat Immunol [Internet]. Nature Publishing Group, 1
  14. Nielsen JS, 2012, Clin Cancer Res. Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada. jnielsen@bccancer.bc.ca: AACR, 18, 3281
  15. Matsumoto H, 2015, J Clin Pathol. Department of Pathology, Singapore General Hospital, Singapore, Singapore Department of Pathology, Ryukyu University Hospital, Okinawa, Japan.; Department of Medical Oncology, National Cancer Centre, Singapore, Singapore.; Department of Medical Oncology;
  16. Quinn DI, 2015, Urol Oncol. Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer, Los Angeles, CA.Carolina Urologic Research Center, Myrtle Beach, SC.; Department of Urology, Jikei University School of Med: The Authors. Published by Elsevier Inc

Cited by

See all 82

Metadata

Authors
Koti, M., Xu, A. S., Ren, K. Y. M., Visram, K., Ren, R., Berman, D. M., & Siemens, D. R.
Affiliations
Queen's University (CA)
Corresponding author
Koti, Madhuri
Venue
Bladder Cancer
Published
2017-10-27
Volume
3
Issue
4
Pages
259-267
ISSN
  • 2352-3727 (ISSN-L)
  • 2352-3735
OpenAlex
W2767198233
Cited by
78
References
23
Citations by year
2026: 5 · 2025: 6 · 2024: 23 · 2023: 14 · 2022: 9 · 2021: 7 · 2020: 7 · 2019: 7
FWCI
3.92
Type
journal article
Language
en
Open access
Locations
  • Bladder Cancer (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
Keywords
tertiary lymphoid structures, bladder urothelial carcinoma, tumor stage, muscle-invasive bladder cancer, non-muscle-invasive bladder cancer, germinal center, B cell response, tumor immune microenvironment, high endothelial venules, follicular dendritic cells, tumor progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder Cancer. https://app.cochat.ai/papers/10.3233/blc-170120
The paper
Koti, M., Xu, A. S., Ren, K. Y. M., Visram, K., Ren, R., Berman, D. M., & Siemens, D. R. (2017). Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder Cancer. Bladder Cancer. https://doi.org/10.3233/blc-170120

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.